FTC Investigates Teva Pharmaceuticals Over Asthma and COPD Inhaler Patents

Teva faces allegations of using minor product changes to maintain market exclusivity and block generic competition.

The FTC has issued a subpoena demanding Teva's internal communications, analysis, and financial data related to the contested patents.
Teva must comply with the FTC's demands by July 24.
The investigation is part of a broader effort to address high drug prices and alleged 'junk' patent listings.
Teva maintains that its patents are properly listed and compliant with regulations.
The case highlights ongoing tensions between pharmaceutical companies and lawmakers over patent practices.